Roche Holding AG

ROG

CH0012032048

Pharmaceuticals

Real-time Estimate Cboe Europe Other stock markets 11:20:00 2025-07-09 am EDT			5-day change	1st Jan Change
258.95 ^CHF	+0.49%		-0.50%	+1.29%

02:25am	ROCHE HOLDINGS AG : JP Morgan reaffirms its Sell rating	ZD
Jul. 08	Deutsche Bank Remains Cautious on Pharmaceutical Sector Ahead of Earnings Season	FW

ROCHE HOLDINGS AG : Deutsche Bank remains a Sell rating

Published on 06/05/2025 at 05:20

Deutsche Bank analyst Emmanuel Papadakis reiterate his Sell rating on the stock. The target price remains set at CHF 250.

Latest news about Roche Holding AG

ROCHE HOLDINGS AG : JP Morgan reaffirms its Sell rating	02:25am	ZD
Deutsche Bank Remains Cautious on Pharmaceutical Sector Ahead of Earnings Season	Jul. 08	FW
ROCHE HOLDINGS AG : Deutsche Bank gives a Sell rating	Jul. 08	ZD
European shares fall as banks, mining stocks losses weigh	Jul. 04	RE
Swiss Market Index Closes Flat; Drugmakers Gain on US-Swiss Trade Deal Talks	Jul. 04	MT
ROCHE HOLDINGS AG : Goldman Sachs reaffirms its Sell rating	Jul. 04	ZD
Roche's Lebanese Unit Renews Healthcare Collaboration with Universities	Jul. 03	MT
Berenberg Cuts Zealand Pharma's Price Target Amid Increased Competition	Jul. 01	MT
ROCHE HOLDINGS AG : UBS reaffirms its Buy rating	Jul. 01	ZD
Amgen says gastric cancer drug meets main goal in late-stage trial	Jun. 30	RE
Rakovina Therapeutics Inc. Highlights Strong H1 Progress and Unveils Strategic Priorities for H2 2025	Jun. 30	CI
ROCHE HOLDINGS AG : Receives a Sell rating from JP Morgan	Jun. 30	ZD
Roche Head of Pharma Research and Early Development to Retire	Jun. 30	DJ
Bayer Receives EU Approval for Extended Eylea Treatment Intervals	Jun. 27	DP
Roche Diagnostics, Egypt's UPA Partner to Advance Green Procurement in Healthcare	Jun. 26	MT
Roche Holding AG - Special Call	Jun. 23
Lineage Cell Therapeutics, Inc. Announces 36-Month Visual Acuity Results Featured at Clinical Trials at the Summit 2025	Jun. 23	CI
Roche: positive Phase I/II data in hemophilia A	Jun. 23	CF
Roche's Hemophilia Drug Shows Hemostatic Normalization Potential in Early-stage Study	Jun. 23	MT
Swiss stocks - Factors to watch on June 23	Jun. 23	RE
Roche's Investigational Therapy for Lymphoma Demonstrates 'Significant' Improvement	Jun. 22	MT
Roche's Lymphoma Treatment Shows Promise in Late-Stage Trial	Jun. 20	DJ
Obesity: preserving muscle, the new challenge	Jun. 19
Swiss trade surplus at CHF 3.831 bln in May	Jun. 19	RE
Fat, not muscle: Drugmakers in race for next weight-loss breakthrough	Jun. 18	RE

Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.

Employees

103,249

Sector

Pharmaceuticals

Calendar

Jul. 24 - Q2 2025 Earnings Release

More about the company